MedTrace Logo

Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF

NCT02690064 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-01-28

No results posted yet for this study

Summary

Cystic fibrosis has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections. However, the physiological mechanisms for this reduced exercise capacity are unknown. The investigators recently published the first evidence of systemic vascular dysfunction in patients with CF. Therefore, it is reasonable to suspect that the blood vessels are involved with exercise intolerance in CF. This study will look at how and if oxidative stress contributes to both artery dysfunction and exercise intolerance in CF.

Conditions

Interventions

DIETARY_SUPPLEMENT

Acute Antioxidant

Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment

DIETARY_SUPPLEMENT

Chronic Antioxidant

Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.

OTHER

Placebo

Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment

Sponsors & Collaborators

  • Augusta University

    lead OTHER

Principal Investigators

  • Ryan Harris, Ph.D. · Augusta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
7 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2026-12-31
Completion
2027-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02690064 on ClinicalTrials.gov